



World Society of Paediatric Ophthalmology & Strabismus

Low Dose Atropine (LDA)

Bulletin 2025



LOW DOSE ATROPINE (LDA) BULLETIN – 2025

INTRODUCTION

The World Society of Paediatric Ophthalmology and Strabismus (WSPOS) recognises low-dose atropine eye drops as a safe, evidence-based, and effective intervention for slowing myopia progression in children, supported by Level 1 evidence across multiple high-quality clinical trials. While variability in efficacy has been reported—largely attributable to differences in formulation quality, variable concentration of atropine, population characteristics, and study design—the collective body of evidence supports low-dose atropine as an important component of a comprehensive myopia-control strategy.

GLOBAL AVAILABILITY OF LOW-DOSE ATROPINE EYE DROPS

Commercially manufactured low-dose atropine eye drops are now available and utilised in many parts of the world including, the United Kingdom, the European Union, Singapore, Japan, China, India, Hong Kong, Colombia, Chile, Peru, Mexico, Kenya (imported) and Australia. These regions have established regulatory-approved production pathways that ensure predictable dosing, product stability, and safety. By contrast, North America along with much of Africa remain without a regulatory-approved commercial formulation and continue to rely on compounded preparations, which are inherently more variable.

CALL FOR HARMONISED, HIGH-QUALITY REGULATORY STANDARDS

WSPOS supports the global harmonization of high-quality regulatory approved commercial formulations and encourages clinicians, regulators, and industry partners to work collaboratively to expand access to safe, reliable low-dose atropine eye drops for children worldwide.